β-Lapachone and Paclitaxel Combination Micelles with Improved Drug Encapsulation and Therapeutic Synergy as Novel Nanotherapeutics for NQO1-Targeted Cancer Therapy

Molecular Pharmaceutics

Volumn 12, Issue 11, 2015, Pages 3999-4010

  Zhang, Ling ^a   Chen, Zhen ^a   Yang, Kuan ^a   Liu, Chun ^a   Gao, Jinming ^b   Qian, Feng ^a  

^a Tsinghua University   (China)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

crystallization; NSCLC; pancreatic cancer; physical interaction; polymeric micelles; therapeutic synergy; lapachone

Indexed keywords

BETA LAPACHONE; PACLITAXEL; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; BETA-LAPACHONE; DRUG CARRIER; MICELLE; NAPHTHOQUINONE; NQO1 PROTEIN, HUMAN; POLYMER; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE);

APOPTOSIS; AQUEOUS SOLUTION; ARTICLE; CANCER CELL; CARBON NUCLEAR MAGNETIC RESONANCE; CONTROLLED STUDY; CRYSTALLIZATION; DIFFERENTIAL SCANNING CALORIMETRY; DRUG FORMULATION; DRUG POTENTIATION; DRUG RELEASE; DRUG SOLUTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; MICELLE; MOLECULARLY TARGETED THERAPY; NANOTECHNOLOGY; POLYMERIZATION; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; CELL PROLIFERATION; CHEMISTRY; COMBINATION DRUG THERAPY; DRUG DELIVERY SYSTEM; DRUG EFFECTS; LUNG NEOPLASMS; METABOLISM; PANCREATIC NEOPLASMS; PATHOLOGY; PROCEDURES; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANTI-INFECTIVE AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, NON-SMALL-CELL LUNG; CELL PROLIFERATION; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG LIBERATION; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HUMANS; LUNG NEOPLASMS; MICELLES; NAD(P)H DEHYDROGENASE (QUINONE); NANOTECHNOLOGY; NAPHTHOQUINONES; PACLITAXEL; PANCREATIC NEOPLASMS; POLYMERS; TUMOR CELLS, CULTURED;

EID: 84946434474     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/acs.molpharmaceut.5b00448     Document Type: Article

References (58)

1. Gomez Castellanos, J. R.; Prieto, J. M.; Heinrich, M. Red Lapacho (Tabebuia impetiginosa) - a global ethnopharmacological commodity? J. Ethnopharmacol. 2009, 121 (1) 1-13 10.1016/j.jep.2008.10.004
2. Pink, J. J.; Planchon, S. M.; Tagliarino, C. et al. NAD(P)H:Quinone oxidoreductase activity is the principal determinant of beta-lapachone cytotoxicity J. Biol. Chem. 2000, 275 (8) 5416-24 10.1074/jbc.275.8.5416
3. De Almeida, E. R. Preclinical and clinical studies of lapachol and beta-lapachone Open Nat. Prod. J. 2009, 2, 42-47 10.2174/1874848100902010042
4. Bentle, M. S.; Bey, E. A.; Dong, Y. et al. New tricks for old drugs: the anticarcinogenic potential of DNA repair inhibitors J. Mol. Histol. 2006, 37 (5-7) 203-18 10.1007/s10735-006-9043-8
5. Dinkova-Kostova, A. T.; Talalay, P. NAD(P)H:quinone acceptor oxidoreductase 1 (NQO1), a multifunctional antioxidant enzyme and exceptionally versatile cytoprotector Arch. Biochem. Biophys. 2010, 501 (1) 116-23 10.1016/j.abb.2010.03.019
6. Nioi, P.; Hayes, J. D. Contribution of NAD(P)H:quinone oxidoreductase 1 to protection against carcinogenesis, and regulation of its gene by the Nrf2 basic-region leucine zipper and the arylhydrocarbon receptor basic helix-loop-helix transcription factors Mutat. Res., Fundam. Mol. Mech. Mutagen. 2004, 555 (1-2) 149-71 10.1016/j.mrfmmm.2004.05.023
7. Bey, E. A.; Bentle, M. S.; Reinicke, K. E. et al. An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone Proc. Natl. Acad. Sci. U. S. A. 2007, 104 (28) 11832-7 10.1073/pnas.0702176104
8. Belinsky, M.; Jaiswal, A. K. NAD(P)H:quinone oxidoreductase1 (DT-diaphorase) expression in normal and tumor tissues Cancer Metastasis Rev. 1993, 12 (2) 103-17 10.1007/BF00689804
9. Jaiswal, A. K. Regulation of genes encoding NAD(P)H:quinone oxidoreductases Free Radical Biol. Med. 2000, 29 (3-4) 254-62 10.1016/S0891-5849(00)00306-3
10. Reinicke, K. E.; Bey, E. A.; Bentle, M. S. et al. Development of beta-lapachone prodrugs for therapy against human cancer cells with elevated NAD(P)H:quinone oxidoreductase 1 levels Clin. Cancer Res. 2005, 11 (8) 3055-64 10.1158/1078-0432.CCR-04-2185
11. Lien, Y. C.; Kung, H. N.; Lu, K. S. et al. Involvement of endoplasmic reticulum stress and activation of MAP kinases in beta-lapachone-induced human prostate cancer cell apoptosis Histol. Histopathol. 2008, 23 (11) 1299-308
12. Ough, M.; Lewis, A.; Bey, E. A. et al. Efficacy of beta-lapachone in pancreatic cancer treatment: exploiting the novel, therapeutic target NQO1 Cancer Biol. Ther. 2005, 4 (1) 102-9 10.4161/cbt.4.1.1382
13. Lewis, A. M.; Ough, M.; Hinkhouse, M. M. et al. Targeting NAD(P)H:quinone oxidoreductase (NQO1) in pancreatic cancer Mol. Carcinog. 2005, 43 (4) 215-24 10.1002/mc.20107
14. Awadallah, N. S.; Dehn, D.; Shah, R. J. et al. NQO1 expression in pancreatic cancer and its potential use as a biomarker Appl. Immunohistochem. Mol. Morphol. 2008, 16 (1) 24-31 10.1097/PAI.0b013e31802e91d0
15. Nasongkla, N.; Wiedmann, A. F.; Bruening, A. et al. Enhancement of solubility and bioavailability of beta-lapachone using cyclodextrin inclusion complexes Pharm. Res. 2003, 20 (10) 1626-33 10.1023/A:1026143519395
16. Blanco, E.; Bey, E. A.; Khemtong, C. et al. Beta-lapachone micellar nanotherapeutics for non-small cell lung cancer therapy Cancer Res. 2010, 70 (10) 3896-904 10.1158/0008-5472.CAN-09-3995
17. Hartner, L.; Rosen, L.; Hensley, M. et al. Phase 2 dose multi-center, open-label study of ARQ 501, a checkpoint activator, in adult patients with persistent, recurrent or metastatic leiomyosarcoma (LMS) J. Clin Oncol 2007, 25, 20521
18. Kawecki, A.; Adkins, D.; Cunningham, C. et al. A phase II study of ARQ 501 in patients with advanced squamous cell carcinoma of the head and neck J. Clin Oncol 2007, 25, 16509
19. Khong, H.; Dreisbach, L.; Kindler, H. et al. A phase 2 study of ARQ 501 in combination with gemcitabine in adult patients with treatment naive, unresectable pancreatic adenocarcinoma J. Clin Oncol 2007, 25, 15017
20. Shapiro, G.; Supko, J.; Ryan, D. et al. Phase I trial of ARQ 501, an activated checkpoint therapy (ACT) agent, in patients with advanced solid tumors J. Clin. Oncol 2005, 23, 3042
21. Gaucher, G.; Marchessault, R. H.; Leroux, J. C. Polyester-based micelles and nanoparticles for the parenteral delivery of taxanes J. Controlled Release 2010, 143 (1) 2-12 10.1016/j.jconrel.2009.11.012
22. Kim, T. Y.; Kim, D. W.; Chung, J. Y. et al. Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies Clin. Cancer Res. 2004, 10 (11) 3708-16 10.1158/1078-0432.CCR-03-0655
23. Cabral, H.; Kataoka, K. Progress of drug-loaded polymeric micelles into clinical studies J. Controlled Release 2014, 190, 465-76 10.1016/j.jconrel.2014.06.042
24. He, C.; Hu, Y.; Yin, L. et al. Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles Biomaterials 2010, 31 (13) 3657-66 10.1016/j.biomaterials.2010.01.065
25. Zheng, N.; Dai, W.; Du, W. et al. A novel lanreotide-encoded micelle system targets paclitaxel to the tumors with overexpression of somatostatin receptors Mol. Pharmaceutics 2012, 9 (5) 1175-88 10.1021/mp200464x
26. Blanco, E.; Bey, E. A.; Dong, Y. et al. Beta-lapachone-containing PEG-PLA polymer micelles as novel nanotherapeutics against NQO1-overexpressing tumor cells J. Controlled Release 2007, 122 (3) 365-74 10.1016/j.jconrel.2007.04.014
27. Singla, A. K.; Garg, A.; Aggarwal, D. Paclitaxel and its formulations Int. J. Pharm. 2002, 235 (1) 179-192 10.1016/S0378-5173(01)00986-3
28. Bonomi, P.; Kim, K.; Fairclough, D. et al. Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial J. Clin Oncol 2000, 18 (3) 623-31
29. Kelly, K.; Crowley, J.; Bunn, P. A., Jr. et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial J. Clin Oncol 2001, 19 (13) 3210-8
30. D'Anneo, A.; Augello, G.; Santulli, A. et al. Paclitaxel and beta-lapachone synergistically induce apoptosis in human retinoblastoma Y79 cells by downregulating the levels of phospho-Akt J. Cell. Physiol. 2010, 222 (2) 433-43 10.1002/jcp.21983
31. Li, C. J.; Li, Y. Z.; Pinto, A. V. et al. Potent inhibition of tumor survival in vivo by beta-lapachone plus taxol: combining drugs imposes different artificial checkpoints Proc. Natl. Acad. Sci. U. S. A. 1999, 96 (23) 13369-74 10.1073/pnas.96.23.13369
32. Planchon, S. M.; Wuerzberger, S.; Frydman, B. et al. Beta-lapachone-mediated apoptosis in human promyelocytic leukemia (HL-60) and human prostate cancer cells: a p53-independent response Cancer Res. 1995, 55 (17) 3706-11
33. Tao, J.; Sun, Y.; Zhang, G. G. et al. Solubility of small-molecule crystals in polymers: D-mannitol in PVP, indomethacin in PVP/VA, and nifedipine in PVP/VA Pharm. Res. 2009, 26 (4) 855-64 10.1007/s11095-008-9784-z
34. Cho, Y. W.; Lee, J.; Lee, S. C. et al. Hydrotropic agents for study of in vitro paclitaxel release from polymeric micelles J. Controlled Release 2004, 97 (2) 249-57 10.1016/j.jconrel.2004.03.013
35. Labarca, C.; Paigen, K. A simple, rapid, and sensitive DNA assay procedure Anal. Biochem. 1980, 102 (2) 344-52 10.1016/0003-2697(80)90165-7
36. Chou, T. C.; Talalay, P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors Adv. Enzyme Regul. 1984, 22, 27-55 10.1016/0065-2571(84)90007-4
37. Cunha-Filho, M. S.; Landin, M.; Martinez-Pacheco, R. et al. Beta-lapachone Acta Crystallogr., Sect. C: Cryst. Struct. Commun. 2006, 62 (8) o473-5 10.1107/S0108270106021706
38. Zhu, Q.; Harris, M. T.; Taylor, L. S. Time-resolved SAXS/WAXS study of the phase behavior and microstructural evolution of drug/PEG solid dispersions Mol. Pharmaceutics 2011, 8 (3) 932-9 10.1021/mp200041j
39. Nishi, T.; Wang, T. Melting point depression and kinetic effects of cooling on crystallization in poly (vinylidene fluoride)-poly (methyl methacrylate) mixtures Macromolecules 1975, 8 (6) 909-915 10.1021/ma60048a040
40. Hoei, Y.; Yamaura, K.; Matsuzawa, S. A lattice treatment of crystalline solvent-amorphous polymer mixtures on melting point depression J. Phys. Chem. 1992, 96 (26) 10584-10586 10.1021/j100205a002
41. Sun, Y.; Tao, J.; Zhang, G. G. et al. Solubilities of crystalline drugs in polymers: an improved analytical method and comparison of solubilities of indomethacin and nifedipine in PVP, PVP/VA, and PVAc J. Pharm. Sci. 2010, 99 (9) 4023-31 10.1002/jps.22251
42. Chen, Y.; Liu, C.; Chen, Z. et al. Drug-polymer-water interaction and its implication for the dissolution performance of amorphous solid dispersions Mol. Pharmaceutics 2015, 12 (2) 576-89 10.1021/mp500660m
43. Matsumura, Y.; Maeda, H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs Cancer Res. 1986, 46 (12 Pt 1) 6387-92
44. Vasey, P. A.; Kaye, S. B.; Morrison, R. et al. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee Clin. Cancer Res. 1999, 5 (1) 83-94
45. Liboiron, B. D.; Mayer, L. D. Nanoscale particulate systems for multidrug delivery: towards improved combination chemotherapy Ther. Delivery 2014, 5 (2) 149-71 10.4155/tde.13.149
46. Morton, S. W.; Lee, M. J.; Deng, Z. J. et al. A nanoparticle-based combination chemotherapy delivery system for enhanced tumor killing by dynamic rewiring of signaling pathways Sci. Signaling 2014, 7 (325) ra44 10.1126/scisignal.2005261
47. Rahib, L.; Smith, B. D.; Aizenberg, R. et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States Cancer Res. 2014, 74 (11) 2913-21 10.1158/0008-5472.CAN-14-0155
48. Hidalgo, M. Pancreatic cancer N. Engl. J. Med. 2010, 362 (17) 1605-17 10.1056/NEJMra0901557
49. Erkan, M.; Hausmann, S.; Michalski, C. W. et al. The role of stroma in pancreatic cancer: diagnostic and therapeutic implications Nat. Rev. Gastroenterol. Hepatol. 2012, 9 (8) 454-67 10.1038/nrgastro.2012.115
50. Li, L. S.; Bey, E. A.; Dong, Y. et al. Modulating endogenous NQO1 levels identifies key regulatory mechanisms of action of beta-lapachone for pancreatic cancer therapy Clin. Cancer Res. 2011, 17 (2) 275-85 10.1158/1078-0432.CCR-10-1983
51. Hata, T.; Furukawa, T.; Sunamura, M. et al. RNA interference targeting aurora kinase a suppresses tumor growth and enhances the taxane chemosensitivity in human pancreatic cancer cells Cancer Res. 2005, 65 (7) 2899-905 10.1158/0008-5472.CAN-04-3981
52. Murakami, M.; Cabral, H.; Matsumoto, Y. et al. Improving drug potency and efficacy by nanocarrier-mediated subcellular targeting Sci. Transl. Med. 2011, 3 (64) 64ra2 10.1126/scitranslmed.3001385
53. Gao, X.; Huang, Y.; Makhov, A. M. et al. Nanoassembly of surfactants with interfacial drug-interactive motifs as tailor-designed drug carriers Mol. Pharmaceutics 2013, 10 (1) 187-98 10.1021/mp300319m
54. Shin, H. C.; Alani, A. W.; Rao, D. A. et al. Multi-drug loaded polymeric micelles for simultaneous delivery of poorly soluble anticancer drugs J. Controlled Release 2009, 140 (3) 294-300 10.1016/j.jconrel.2009.04.024
55. Shin, H. C.; Alani, A. W.; Cho, H. et al. A 3-in-1 polymeric micelle nanocontainer for poorly water-soluble drugs Mol. Pharmaceutics 2011, 8 (4) 1257-65 10.1021/mp2000549
56. Rowinsky, E. K.; Jiroutek, M.; Bonomi, P. et al. Paclitaxel steady-state plasma concentration as a determinant of disease outcome and toxicity in lung cancer patients treated with paclitaxel and cisplatin Clinical cancer research: an official journal of the American Association for Cancer Research 1999, 5 (4) 767-74
57. Bonomi, P. Review of paclitaxel/carboplatin in advanced non-small cell lung cancer Seminars in oncology 1999, 26 (1 Suppl 2) 55-9
58. Von Hoff, D. D.; Ervin, T.; Arena, F. P. et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine N. Engl. J. Med. 2013, 369 (18) 1691-703 10.1056/NEJMoa1304369